DWA
TCRT icon

Douglass Winthrop Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Douglass Winthrop Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-93
Closed -$71K – 272
2014
Q4 		$71K Buy
93
+13
+16% +$6.9K 0.01% 213
2014
Q3 		$32K Hold
80
– – ﹤0.01% 196
2014
Q2 		$48K Buy
80
+13
+19% +$7.24K ﹤0.01% 188
2014
Q1 		$46K Hold
67
– – ﹤0.01% 190
2013
Q4 		$43K Buy
+67
New +$39.9K ﹤0.01% 188

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Douglass Winthrop Advisors's TCRT Position: Q1 2015 in Review

Douglass Winthrop Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2015, closing a stake of 93 shares — an estimated $71K sold.

Douglass Winthrop Advisors first reported a position in TCRT in Q4 2013 and held it in 5 quarters. The position peaked at $71K in Q4 2014. 128 funds tracked by Wall St. Rank hold TCRT as of Q1 2015.

  • Douglass Winthrop Advisors reported no remaining Alaunos Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Douglass Winthrop Advisors sold 93 Alaunos Therapeutics shares in Q1 2015, an estimated $71K.
  • Douglass Winthrop Advisors first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 5 quarters.
  • Douglass Winthrop Advisors's Alaunos Therapeutics position peaked at $71K in Q4 2014.
  • 128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2015.

Based on Douglass Winthrop Advisors's 13F filing for Q1 2015, filed 29 Apr 2015.